

**This document is only for open comments and not final.
Do not cite or distribute.
Submit comments to practice@aana.com**

Enhanced Recovery after Surgery
Considerations for Pathway Development and Implementation

1
2
3

Table of Contents	
Introduction	2
Purpose	2
Audience	2
The Patient's Interdisciplinary Team	2
Culture and Leadership	3
Enhanced Recovery after Surgery Pathway Development	3
Begin with the Project Plan	3
Project Vision and Strategy	3
Pathway Development	4
Change Management	4
Kotter's 8 Step Change Model	5
Enhanced Recovery after Surgery Pathway Trial Implementation	6
Coordination of Care Support	6
Prehospital/Preadmission Phase	7
Preoperative Phase	8
Intraoperative Phase	9
Postoperative Phase	14
Discharge Phase	15
Post-Discharge Phase	15
Continued Quality Improvement Team Activities	15
What Data to Collect	15
Data Collection	16
Translating Data to Action	16
Addressing Implementation Challenges	16
Conclusion	17
Enhanced Recovery Resources	17
References	21
Appendix	28

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

This document is only for open comments and not final.

Do not cite or distribute.

Submit comments to practice@aana.com

21 **Introduction**

22 Enhanced Recovery after Surgery (ERAS) refers to patient-centered, evidence-based,
23 interdisciplinary team-developed pathways for a surgical specialty and facility culture to reduce
24 the patient's surgical stress response, optimize their physiologic function, and facilitate
25 recovery.¹⁻⁵ Originally developed for colorectal surgery in Denmark in the late 1990s, ERAS
26 pathways have been successfully implemented in many other specialties, including pancreatic,
27 gynecologic, cardiovascular, thoracic, pediatric, orthopedic, and urologic surgery.^{1-4,6}

28 Terms such as fast-track, rapid, or accelerated recovery programs are similar but do not
29 encompass the comprehensive culture of care represented by the pathway that engages the
30 patient from their first visit to their surgeon's office through 30-90 days post-discharge. An
31 ERAS pathway and program represent a fundamental shift away from each individual clinician's
32 practice decisions to one that uses a procedure- and facility-specific pathway that limits
33 variability yet can be modified to address each patient's unique needs. The interdisciplinary
34 team reports and analyzes quality measures to continuously improve the pathway and patient
35 outcomes.^{7,8} While each facility has its own definition of what ERAS does, facilities can pull
36 information from this document and tailor it to their needs.

37 Growing evidence suggests that ERAS contributes to improved patient outcomes,^{7,8} reduces
38 postoperative complications,^{3,7,9} decreases the occurrence of wound infections,³ accelerates
39 recovery,^{7,8} reduces the use of opioids,^{10,11} and supports early discharge,^{10,11} with savings from
40 decreased length of stay,¹²⁻¹⁵ complications, and readmission offsetting increased cost of
41 care.^{9,14} Though individual elements of an ERAS pathway are beneficial, implementation and
42 compliance with patient-appropriate elements of a comprehensive pathway across the entire
43 perioperative continuum have been shown to improve outcomes. Each patient must be
44 evaluated for the value and appropriateness of the enhanced recovery pathway in their plan of
45 care. The key elements of ERAS include patient/family education, patient optimization prior to

46 admission, minimal fasting that optimally includes a carbohydrate beverage and, at a minimum,
47 clear fluids up until 2 hours before anesthesia, multimodal analgesia with appropriate use of
48 opioids when indicated, returning to a normal diet and activities the day of surgery, and
49 returning home.^{5,6,11,14-17}

50

51 **Purpose**

52 These practice considerations are intended to support the anesthesia professional as a member
53 of the interdisciplinary team that includes the patient and in implementing and continually
54 improving ERAS pathways across the continuum of care from before admission to returning
55 home. By collaboratively developing specialty- and facility-specific evidence-based ERAS
56 pathways, the team limits individual provider variation in care to improve patient engagement,
57 quality of recovery, safety, and outcomes. As members of the interdisciplinary team, anesthesia
58 professionals are well-positioned to lead and collaborate to successfully implement ERAS
59 pathways across the perioperative period.

60

61 **Audience**

62 These practice considerations are written for facilities that currently utilize or would like to
63 implement an ERAS program into their perioperative period.

64

65 ***The Patient's Interdisciplinary Team***

66 An interdisciplinary team refers to a group of healthcare professionals from diverse fields who
67 work together in a cohesive and collaborative fashion with trust to share expertise, knowledge,
68 and skills to engage and optimize the patient across the entire pathway.^{7,17-20} The anesthesia
69 professional integrates the core values of their profession and practice to optimize patient and
70 team communication, patient safety, and evidence-based practice.^{7,17-20} The interdisciplinary

This document is only for open comments and not final.

Do not cite or distribute.

Submit comments to practice@aana.com

71 team supports the patient, as an active member of the team, to contribute to the development of
72 the plan of care and realistic goals for recovery.^{18,21}

73

74 Most effective change begins with a small, engaged team that is interested in continued
75 improvement. Team success is optimized when initial learning and ongoing education, training,
76 and development are core to engagement and the continued improvement of the program.²¹

77 The opportunity to develop and pilot a unique, evidence-based, and valuable initiative can be a
78 powerful motivator. The first step after leadership buy-in is the development of an enhanced
79 recovery pathway, which involves the identification of a surgical specialty (e.g., colorectal,
80 gynecologic, oncology surgery) that has an interest in the creation and implementation of an
81 ERAS pathway. Beginning with a small team (e.g., one pathway, one surgeon) and gradually
82 refining the original pathway prior to a larger program rollout will keep the process on track and
83 help identify any implementation gaps for improvement.

84

85 ***Culture and Leadership***

86 Building a successful ERAS program goes far beyond simply creating a protocol or a pathway.²⁰

87 Translating change across the care continuum into practice takes considerable effort for
88 patients, healthcare professionals and organizations. It requires committed and engaged
89 leadership that creates and invests in a sustainable culture of trust, learning, communication,
90 and effective teamwork.^{20,21} Effective leaders are able to:^{9,20-22,}

- 91 • Communicate to support the vision and culture necessary for the comprehensive, long-
92 term program.
- 93 • Create a strategic plan or roadmap to guide the program.
- 94 • Encourage engagement and commitment to ownership, and continued excellence from
95 all participants.

96

97 **Enhanced Recovery after Surgery Pathway Development**

98 Successful change management and implementation occur as a process that evolves from the
99 creation of the climate for change to the engagement and empowerment of those involved
100 through the development of the change initiative, the implementation or trial of the pathway, and
101 sustained change with continued improvement.²³ Project and change management techniques
102 and tools are not universally part of an entry-level healthcare education program curriculum.
103 Partnering with professionals in your facility and accessing tools and literature will be helpful in
104 managing the scope of this project.^{24,25} Project management, safety, and team training
105 resources are helpful considerations when embarking on a change initiative of this magnitude.
106 The team's success in creating a specialty enhanced recovery pathway is also leveraged
107 through learning from the experience of others by joining a collaborative network of colleagues
108 by attending meetings or contributing to a related listserv, as well as the continued review of the
109 literature and practice outcomes.

110

111 ***Begin with the Project Plan***

112 Even before engaging the team in the idea of creating an ERAS pathway, it is necessary for the
113 project leadership team to develop the project plan to assess the scope of the project.
114 Elements of the project plan include readiness, pre-implementation, implementation and
115 readiness, and evaluation.²⁶ During the assessment of readiness, the team reviews the related
116 literature, existing protocols, case studies, the current program's data, and benchmark
117 information from similar internal and external projects to provide the team with information to
118 create a project charter and plan.²⁷ The project plan includes the identification of factors that
119 may facilitate or impede the project.^{28,29}

120

121 ***Project Vision and Strategy***

122 Next, an assessment of staff readiness and capability to support the change is helpful during the
123 development of the project strategy and vision. One approach to identifying related elements
124 unique to your facility culture and people's biases related to their own practice and ERAS is to
125 conduct focus sessions, surveys, and individual interviews with representative members of the
126 practice. Consider the following questions:³⁰

- 127 • Perception of the current state. What is working well and not working well with patient
128 preparation, patient ambulation the day of surgery, pain management, and other areas
129 of interest?
- 130 • Who should lead the change? Who is a trusted thought leader?
- 131 • What needs to be done and changed to implement the change?
- 132 • What resources (e.g., staff, equipment) do we have, and what will be required?
- 133 • Who or which specialty is prepared to trial the pathway?
- 134 • What is the timeline to develop and implement the change?
- 135 • What training and materials need to be developed for all staff and patients?

136

137 ***Pathway Development***

138 The definition and development of facility- and culture-specific care pathway(s) is accomplished
139 through a systematic review of outcome data, published ERAS guidelines, protocols, and trials.
140 The review is based not only on the quality of the evidence, but also on an analysis of how the
141 ERAS program may fit with the culture of the practice, its skills, and its resources.²⁴ The
142 perioperative members of the ERAS team represent the patient and family, the surgeon's office,
143 preanesthesia, nursing units, surgery, anesthesia, administration, patient education, and
144 representatives of other core professions. This team reviews the evidence, assesses current
145 practice and culture, and decides which pathway(s) should be implemented in the practice.

This document is only for open comments and not final.

Do not cite or distribute.

Submit comments to practice@aana.com

146 Additionally, facilities with an “ERAS Coordinator” have increased staff education and can solely
147 focus on the implementation process.³¹ It is always beneficial to partner with other specialties
148 and facilities that have an ERAS program to learn from their experience and identify successes
149 and barriers.³⁰

150

151 ***Change Management***

152 There are many models that offer a construct or framework to lead, develop, implement, and
153 sustain successful change initiatives. Kotter’s 8-Step Change Model offers a framework to
154 generate and implement planned and sustainable change.²³ The model guides the team
155 through the development and implementation of an ERAS pathway.²³

156

157 In March 2017, the Agency for Healthcare Research and Quality (AHRQ) Safety Program for
158 ERAS launched an initiative to increase the implementation of ERAS pathways in U.S. hospitals
159 through the adoption of AHRQ’s Comprehensive Unit-based Safety Program (CUSP).³² The
160 CUSP multifaceted approach facilitates front-line teams to more rapidly adopt evidence-based
161 practices. AHRQ’s Safety Program for Improving Surgical Care and Recovery uses the CUSP
162 framework to promote the delivery of evidence-based perioperative care and prioritize quality
163 improvement.³¹ The CUSP Toolkit supports Kotter’s 8-Step Change Model and is compatible
164 with TeamSTEPPS® to support units in improving culture (See Table 5).³³

165

166

167

168

Step 1. Create a Sense of Urgency

Tell a compelling story for individuals and team to visualize the need and importance of their engagement in the change initiative.

- **Storytelling is key:** A short repeatable story is crucial to capture the project's vision and encourage participation
- **Urgency and Importance:** The story should create a sense of urgency, highlighting the importance of initiative
- **Diverse Teams:** Early engagement is vital because teams have different perspectives
- **Visuals Matter:** Combine spoken and visual elements (like infographics) for clear communication
- **Focus on Benefits:** The story should emphasize how the change improves patient outcomes and staff satisfaction
- **Variable Engagement:** Recognize that staff will engage at different paces and for different reasons

169

Step 2. Form a Powerful Guiding Coalition

Visible, coordinated support from top levels of leadership, key stakeholders and staff thought leaders who will lead the team to design and drive change.

- **ERAS Champions & Leaders:** ERAS success relies on a core team with representatives from various perioperative professions (surgeons, nursing, anesthesia professionals, pharmacists, etc.)
- **Champion Role:**
 - **Education & Communication:** Champions facilitate education and communication within their teams and across professions to raise awareness and acceptance of the ERAS program
 - **Positive Attitude:** They bring a "can-do" attitude to encourage participation
 - **Key Qualities:** There's no perfect champion, but effective ones can clearly explain the program's value, provide direction and motivation, build trust, foster collaboration across professions, and communicate effectively with colleagues

Steps 3 and 4. Create and Communicate the Vision for Change

Develop concise story that can be told in a less than 5 minutes, that is easily understood and remembered.

- **Share the Vision for Change:** Leaders need a clear vision of the desired future state for the program
- **Importance of Buy-In:** Getting everyone on board is crucial for effective change
- **Vision as a Tool:** A clear vision helps people see the benefit and actively contribute to developing a patient-centered pathway
- **Early Involvement:** Including the team in decision-making from the start fosters ownership and reduces resistance to change
- **Focus on Benefits:** Discussing both program goals and potential challenges allows for a more comprehensive plan

Step 5. Empower Broad-based Action

Identify persons, processes and other factors to address the barriers for the engaged team's success.

- **Empowering Action:** Removing barriers to change, both potential and existing, is crucial for broad-based participation
- **Leadership's Role:** Leaders play a central role in overcoming challenges and providing ongoing support to the team
- **Benefits of Empowerment:** Empowering the teams allows them to execute the vision and drive the change forward

Step 6. Generate Short-term Wins

Identify short-term targets to share quick, early victories for celebration of success and to create momentum.

- **Celebrating Success Matters:** Recognizing achievements motivates the team to continue following the ERAS pathway
- **Benefits of Celebration:**
 - **Encourages Compliance:** Celebrating success keeps the team engaged with the ERAS program
 - **Validation & Involvement:** Recognizing achievements validates everyone's contribution to the program's vision
 - **Confidence Building:** Celebrating successes builds confidence in the effectiveness of the ERAS program
 - **Attracts New Participants:** Recognition can draw others who haven't yet participated in the ERAS program

Step 7. Consolidate and Build on Change

Use momentum from quick wins to continue to build on what is going well and to identify improvement opportunities.

- **Beware of Premature Celebration:** Don't declare victory too soon. Celebrate progress, but continued improvement is essential
- **Maintain Focus on Change:** Kotter emphasizes that motivation and teamwork are crucial to solidify the new practices before full transformation is achieved
- **Learn from Wins:** Analyze short-term successes to identify what worked well and what needs improvement. This helps refine the program for better outcomes

Step 8. Anchor Changes into Organization and Team Culture

The change becomes core to your culture through stories, recognition, orientation, and recruiting.

- **ERAS as a Journey:** Don't see ERAS as a one-time fix, but an ongoing process of improvement
- **Long-Term Sustainability:** To keep ERAS successful in the long run, several things are important:
 - **Continued Leadership:** Leaders need to stay involved and contribute to the program's ongoing development
 - **Team Education:** Provide ongoing education and training for the team to ensure everyone stays up-to-date
 - **Progress Updates:** Keep the team informed about the program's progress to maintain momentum
 - **Celebrating Wins:** Recognize short-term successes to keep the team motivated and enthusiastic
- **Ultimate Goal:** The goal is for ERAS to become a natural part of everyday practice

170

171 **Enhanced Recovery after Surgery Pathway Trial Implementation**

172 Following the development of the project plan and enhanced recovery pathway, the acquisition
173 of necessary supplies and medications, the creation of patient education resources, the
174 completion of trial team staff education, and many other elements, it is time to trial a case or
175 several cases to identify successes and gaps in your preparation and execution. ERAS-related
176 practice areas and roles vary across specialties, patients, facilities, and health systems.

177

178 ***Coordination of Care Support***

179 Little takes the place of the value and effectiveness of face-to-face communication. Electronic
180 health records (EHR) that are interfaced to support the coordination of care for patient safety
181 and modification of the patient specific plan of care across the various practice settings and
182 transitions of care. These transitions include prehospitalization through the patient's return
183 home for recovery, therapy when necessary, and follow-up with surgeons, primary- and
184 specialty-care providers. Integrating electronic health records and scheduling systems
185 improves the safety, compliance, and efficiency of the ERAS program.³⁴ When EHR products
186 do not interface or are not available, it is important to assess communication handoff pathways
187 and tools to optimize safe care.

188

189 ***Patient Engagement***

190 Patient education and expectation management in the Prehospital/Preadmission phase are
191 critical to the success of the ERAS program. The patient learns about the ERAS program and
192 establishes realistic goals for pain after surgery, nutrition, mobilization, and the expected
193 hospital stay.³⁵ Education may also encourage the patient to engage in a physical activity or
194 nutrition program to get in a better physical condition prior to the procedure to improve
195 outcomes.^{36,37}

This document is only for open comments and not final.

Do not cite or distribute.

Submit comments to practice@aana.com

196 Patient-related barriers to ERAS implementation include understanding why the perioperative
197 processes they have come to expect have changed. Providing early education in the
198 community and in the surgeon's office allows the patient to be a significant contributor to their
199 care experience. Patient comorbidities, such as hypertension, hypercholesterolemia, chronic
200 obstructive airway disease, and diabetes, can be optimized preoperatively with careful
201 evaluation and assessment to participate in the ERAS pathway of care. If the patient is found to
202 be a candidate for the pathway, additional planning to optimize their health through
203 prehabilitation prior to surgery is important for a rapid return to health postoperatively.³⁷

204 Multimodal pain management may also be a new concept for patients and their families.
205 Education, success stories, and data are often helpful for the patient to develop a realistic
206 understanding of the multimodal instead of one medication plan for analgesia.³⁸ Patients are
207 also most successful when they are able to actively engage in lifestyle activities, such as
208 exercise to lose weight or stopping smoking more than 2 weeks prior to surgery; ideally as a
209 permanent cessation.²⁹

210 Language, cultural and religious beliefs, and health literacy may also impact a patient's
211 understanding of the enhanced recovery process. Please see the AANA document titled
212 *Informed Consent for Anesthesia Care* for strategies to address communication, health literacy,
213 and cultural competency.³⁹

214 *Engaging Staff*

215 Staff attitudes, biases, and behaviors may also make ERAS implementation challenging.⁴⁰
216 Barriers may be due to resistance to personal practice change related to a limited
217 understanding of ERAS value.^{41,42} It is helpful to educate staff members to support the adoption
218 of ERAS principles in their practice. Education includes the program itself, how their practice
219 will change, and offering new education and skills opportunities that will position the staff

220 member as a successful contributor. Using many channels for effective communication across
221 all ERAS team members contributes to the success of an ERAS program.²⁵ There is much to
222 be done. Breaking down the project into small elements allows multiple teams and individuals
223 to contribute to the success of the pathway from the beginning through implementation and
224 continued improvement.

225 ERAS brings together a diverse team of healthcare professionals, each playing a vital role in
226 empowering patients to actively manage their care. Risk managers, care navigators, pain
227 management services, nutritionists, and social workers often go unnoticed, yet their
228 contributions are essential for a holistic ERAS program.

229 *Engaging the Team and Leadership*

230 Obtaining buy-in from hospital administration and clinical leaders is essential to cultivating and
231 leading improvement within the facility.²² From the initiation stages to the implementation of an
232 ERAS program., leadership roles that are strong supporters and visible champions will set the
233 tone for the upcoming changes and display their commitment.²² Practice-related barriers to
234 ERAS implementation may include limited facility resources, low compliance with the program
235 plan due to leadership, and administrative support.^{29,41} Actively addressing these factors and
236 other pathway barriers through the use of data and communication is critical prior to
237 implementing the ERAS program.

238

239

240 ***Prehospital/Preadmission Phase***

241 *Surgeon's Office*

242 The ERAS pathway begins when the patient visits their surgeon and the office team with a focus
243 on patient education, patient expectations, engagement, and the development of a plan to

This document is only for open comments and not final.

Do not cite or distribute.

Submit comments to practice@aana.com

244 optimize their health before surgery and anesthesia for a rapid return to health post-procedure.²
245 Identification of patients who will enter the pathway and early engagement of the
246 interprofessional team may begin here. Patients, depending on their individual needs and the
247 ERAS pathway they are entering, may meet only a few of the team members. As the
248 complexity of the patient increases, they may not only meet the entire team preoperatively but
249 also partner with the clinical team earlier for prehabilitation and longer post-procedure for
250 successful rehabilitation.

251

252 *Patient Optimization and Prehabilitation*

253 Patients present for surgery and anesthesia with varying states of health. The goal of
254 preprocedure prehabilitation is to identify patients with preexisting chronic and acute conditions
255 in whom physiologic reserves can be improved or optimized prior to surgery.^{2,43} Robust
256 prehabilitation programs should be multimodal, aiming to improve cardiopulmonary capacity and
257 metabolic flexibility through individualized exercise regimens, nutritional enhancements, and
258 psychosocial support.² Creating a preoperative triage system of patient factors (e.g., advanced
259 age,⁴⁴ frailty, cardiovascular deconditioning) and surgical complexity (e.g., major open
260 vascular/abdominal, joint replacement, cardiac surgery on cardiopulmonary bypass)¹⁹ improves
261 patient screening, assessment, and ability to develop the prehabilitation plan when necessary.⁴⁵
262 Though several meta-analyses and randomized trials report the benefits of prehabilitation,
263 further research is needed to measure patient outcomes through combined prehabilitation and
264 ERAS techniques. Cost-effectiveness should also be further explored.⁴³

265

266 Patient assessment and health history collection can occur through a patient portal, telephone
267 interview, and, when appropriate, a preanesthesia assessment clinic to further assess and
268 prepare complex patients for anesthesia and surgery.³⁵ Patient assessment and evaluation

This document is only for open comments and not final.

Do not cite or distribute.

Submit comments to practice@aana.com

269 focus on general health and the patient's functional capacity, and comorbidities to identify risk
270 factors that may prolong recovery or lead to complications. A healthy patient has less to gain
271 from preoperative medical optimization, though they may benefit from a health assessment and
272 discussion of opportunities to maintain and improve their health.⁴⁶ Conditions associated with
273 an increased risk of perioperative complications include cardiovascular disease, hypertension,
274 chronic obstructive pulmonary disease (COPD), anemia, obesity, and diabetes mellitus.⁴⁷ The
275 patient with comorbid conditions should begin assessment and optimization weeks prior to the
276 procedure.

277
278 While certain health factors cannot be modified (e.g., age, extent of disease), there are
279 modifiable elements (e.g., body mass index) that can be improved with exercise and diet
280 modifications to enhance functional reserve.⁴⁸ Patients with low functional and physiologic
281 reserves (e.g., elderly, frail, morbidly obese) may benefit from a plan for prehabilitation to
282 improve physical fitness before surgery.⁴⁸ Addressing cigarette smoking with including
283 cessation referrals, alcohol intake, and nutritional status to identify nutritionally depleted patients
284 is also important to reduce intraoperative complications.³⁵ Some prehabilitation programs use
285 assessment tools, such as cardiopulmonary exercise testing (CPET), to evaluate the patient's
286 exercise capacity preoperatively.⁴⁹

287 288 *Patient/Family Education*

289 The anesthesia professional plays a pivotal role in patient and family education by engaging the
290 patient as an active participant in his or her care and the recovery process.²⁸ Anesthesia
291 professionals continue to build on these activities throughout the Prehospital/Preadmission
292 phase through patient assessment and evaluation to identify unique elements of the patient's
293 health, pain, and anesthesia history that may require modification of the ERAS pathway to

294 coordinate the development of the plan of care with the patient and their primary care and
295 specialty teams, as appropriate.³⁰

296

297 *Pain Management Plan*

298 As part of the preanesthesia assessment, the anesthesia professional discusses with the patient
299 their previous pain experiences and possible intensity of surgical discomfort to offer
300 considerations for elements of a comprehensive perioperative plan to manage surgical pain.
301 Collaboration with the patient's advanced pain management team and utilizing multi-modal pain
302 management strategies can improve outcomes, especially for patients with difficult to control
303 pain (e.g., chronic pain patients, substance use disorders).⁵⁰⁻⁵²

304

305 ***Preoperative Phase***

306 *Psychological Preparation of Surgery*

307 Recent studies have found that patients with anxiety, depression, and catastrophizing attitudes
308 may lead to postoperative complications, impaired recovery, and an increased rate of
309 hospitalization.^{53,54} These patients often experience a maladaptive response to surgical stress,
310 which leads to hypermetabolic and hypercatabolic processes that affect the immune system,
311 wound healing, and organ functionality.⁵⁴ Additionally, acknowledgment of the patient's pain
312 psychology is an important aspect.⁵⁵ Patients who either experience these conditions or are at
313 high risk for their development should be screened, counseled, and referred for treatment prior
314 to undergoing surgery. Preoperative counseling may include setting clear expectations for pain
315 management control and setting a plan for care during postoperative recovery. Please see the
316 AANA document titled *A Holistic Approach to Pain Management: Integrated, Multimodal, and*
317 *Interdisciplinary Treatment* for more on pain psychology.⁵⁵

318

319 *Preoperative Fasting*

320 The most updated reports by the American Society of Anesthesiologists (ASA) Task Force on
321 Preoperative Fasting and the ASA Committee on Standards and Practice Parameters
322 recommend that patients can eat a light meal up to 6 hours preoperatively and a minimum
323 fasting period of between 2 and 4 hours for clear fluids, such as water, fruit juices without pulp,
324 carbonated beverages, carbohydrate-rich nutritional drinks, clear tea, and black coffee.^{56,57}

325 Though the preoperative fasting guidelines have been in place for some time, many anesthesia
326 professionals, for varying reasons, require that the patient be NPO after midnight.

327

328 Current ERAS literature recommends that preoperative fasting time be kept to a minimum to
329 reduce preoperative thirst, hunger, and anxiety, as well as the perception of pain.⁸ In some
330 ERAS pathways, it is recommended that the patient drink 400 – 800 mL of a 12.5 percent
331 carbohydrate-containing clear liquid before midnight on the night before surgery and 400 mL of
332 the same drink up to 2 hours prior to anesthesia.^{17,56-58} Drinking a carbohydrate beverage 2
333 hours prior to the induction of anesthesia has been shown to reduce insulin resistance, minimize
334 nitrogen and protein loss, and maintain muscle strength to accelerate recovery.^{4,56,59,60}

335 However, further research is required for diabetic patients, as the carbohydrate beverage must
336 be considered as part of the glycemic management plan.⁵⁹ Due to this, it is recommended that
337 water be used in lieu of a carbohydrate beverage for patients with diabetes mellitus.⁵⁹

338

339 In addition to 12.5 percent carbohydrate-containing liquids, some patients may benefit from one
340 of the several commercially available nutritionally balanced products on the market. In
341 collaboration with dietary and nutrition services, considerations for selecting an optimal
342 beverage include.^{58,61}

- 343
- Avoidance of renal solute load.

- 344 • Low osmolality.
- 345 • A maltodextrin component for an optimal insulin secretion profile.
- 346 • Pleasant taste.
- 347 • Prepackaged in clinically relevant doses.
- 348 • Available and affordable to patients and hospitals.

349

350 *Discharge Education and Planning*

351 Discharge education and planning begin early in the surgeon's office, during the preoperative
352 phase, and continue through discharge and return home. Early patient education (both written
353 and verbal) and engagement increase understanding of the importance of their contribution and
354 participation in their plan of care for the best outcomes, as well as the ability to monitor the
355 compliance of the entire team in their care pathway.¹⁷ The following activities may be included
356 as part of discharge planning:

- 357 • An understanding of the timing of the elements and goals along the care continuum
358 prepares the patient and their family to participate in the care they will receive.
- 359 • Transitions in the experience of pain and how pain can be managed with medications
360 and non-pharmacologic modalities.
- 361 • Clear instructions about mobilization and diet with daily activity targets to achieve.
- 362 • Circumstances that may delay discharge and how they will be addressed.

363

364 ***Intraoperative Phase***

365 *Multimodal Analgesia*

366 Multimodal analgesia describes the use of more than one modality or technique to achieve
367 effective pain control from the preoperative period through initial recovery and return
368 home.^{7,8,17,60} A multimodal approach, instead of the traditional unimodal opioid approach,

369 involves the administration of several analgesics with separate mechanisms of action across the
370 perioperative period and/or concurrent field block using local anesthetic, regional, or neuraxial
371 analgesia (e.g., paravertebral block with non-opioid analgesia).^{7,10,17} It is important to take into
372 consideration the complexity of the surgical procedure, patient pain experience history and
373 preferences, anticipated level of postoperative pain, and duration of action of analgesics and
374 local anesthetics when deciding on pain management options for pathway development and for
375 individual patients. Multimodal analgesia may eliminate or significantly reduce the use of
376 opioids and adverse side effects such as respiratory depression, postoperative nausea and
377 vomiting (PONV), and delayed return of gastrointestinal function.^{7,10,17} However, low-dose
378 opioids for a defined period of time should be made available when necessary, when other
379 modalities are not effective to address the patient's discomfort. Opioids should be administered
380 in a dose sufficient for adequate analgesia while limiting side effects (e.g., respiratory
381 depression, sedation, nausea, and vomiting).¹⁶

382 Non-opioid medications include acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs),
383 systemic lidocaine infusion or ketamine infusion, long-acting local anesthetics, and
384 gabapentinoids (gabapentin/pregabalin).^{16,17,62-64} Other modalities using local anesthetics of
385 varying durations of action include surgical site local anesthetic infiltration, field blocks (e.g.,
386 transversus abdominis plane (TAP) block), central neuraxial techniques (e.g., epidural and
387 spinal analgesia), and regional blocks.^{16,17,62-64} Non-pharmacological analgesia (e.g.,
388 acupuncture, music therapy) as well as cognitive-behavioral techniques (e.g., guided imagery,
389 relaxation) may be used as an adjunct to pharmacological methods to support the patient in
390 reducing postoperative pain, anxiety, and the use of pain medication.^{10,64}

391

* Caution is suggested for patients over the age of 65 due to the increased risk of delirium, new antipsychotic use, and pneumonia.

392 Several factors to consider when developing a multimodal pain management plan of care with
393 the patient include:^{17,60,64}

- 394 • Patient preferences and previous experience with pain.
- 395 • Medical history, including comorbidities.
- 396 • Emotional and psychological status, including previous related experiences and
397 concerns.
- 398 • Type of surgery and anticipated postsurgical pain experience.
- 399 • The risk-benefit of the various non-opioid multimodal strategies.

400 The following table offers a starting point to begin developing an ERAS multimodal analgesia
401 pathway. Science is changing rapidly as teams review their outcome data. The facility
402 formulary will provide a list of available medications to choose from or to identify medications to
403 request additions to the formulary. In addition to reviewing existing pathways, a review of the
404 literature will provide the team with peer-reviewed evidence to craft and improve their ERAS
405 pathway.

406

**This document is only for open comments and not final.
Do not cite or distribute.
Submit comments to practice@aana.com**

407
408

Table 1. Considerations for Classes of Medications and Local Anesthetic Techniques* to Create Procedure Specific Enhanced Recovery Pathway¹⁷

	Class of Medication/Technique*	Medication	Considerations
Preop	Acetanilide derivative	<ul style="list-style-type: none"> Acetaminophen 	<ul style="list-style-type: none"> Cost-effective (PO) Contraindicated in severe liver impairment or disease
	Cyclooxygenase-2 inhibitor	<ul style="list-style-type: none"> Celecoxib 	<ul style="list-style-type: none"> Selective NSAID subclass with fewer side effects Less risk of perioperative bleeding
	Gabapentinoid	<ul style="list-style-type: none"> Pregabalin Gabapentin 	<ul style="list-style-type: none"> Glutamate inhibitor Increased risk of sedation, confusion, ataxia, visual disturbances, and suicidal ideation⁶³ Increased rate of postoperative adverse events in age > 65 years⁶³
	Nonsteroidal anti-inflammatory drug (NSAID)	<ul style="list-style-type: none"> Ibuprofen Ketorolac 	<ul style="list-style-type: none"> Nonselective (inhibits both COX-1 and COX-2)⁶⁵ Decreases inflammation⁶⁵ Decreased platelet aggregation may result in increased risk of bleeding⁶⁵ Renal elimination⁶⁵
	Regional/neuraxial blockade*	<ul style="list-style-type: none"> Spinal anesthesia Epidural anesthesia/analgesia Nerve blocks 	See <i>Regional Anesthesia Techniques – An Element of Multimodal Pain Management</i> ⁶⁶
Intraop	Acetanilide derivative	<ul style="list-style-type: none"> Acetaminophen 	<ul style="list-style-type: none"> Hepatic toxic metabolite, limit daily dose to 4 grams/day from combination drugs with acetaminophen⁶⁷ IV maximum drug concentration, 70 percent greater than oral; overall drug exposure similar between IV and oral⁶⁷ IV ketorolac and acetaminophen effective for moderate pain in children⁶⁷
	Alpha 2 agonist	<ul style="list-style-type: none"> Dexmedetomidine Clonidine 	<ul style="list-style-type: none"> Anti-hypertensive effect Sedative, anxiolytic, analgesic Side effects: bradycardia, hypotension sedation⁶⁸
	Beta-blocker	<ul style="list-style-type: none"> Esmolol 	<ul style="list-style-type: none"> Avoid in sinus bradycardia, 1st degree heart block, and heart failure May increase digoxin levels

**This document is only for open comments and not final.
Do not cite or distribute.
Submit comments to practice@aana.com**

	Class of Medication/Technique*	Medication	Considerations
	Electrolyte administration	<ul style="list-style-type: none"> • Magnesium sulfate 	<ul style="list-style-type: none"> • Analgesic and anesthetic sparing effects • High therapeutic index • May prolong duration of nondepolarizing neuromuscular blockade
	<ul style="list-style-type: none"> • Infiltration of surgical site with local anesthesia as single dose or infusion 	<ul style="list-style-type: none"> • Bupivacaine • Ropivacaine • Lidocaine • Liposomal Bupivacaine for prolonged release, single-dose administration 	<ul style="list-style-type: none"> • Significant side effects are rare when intravascular injection is avoided • Chondrolysis for intra-articular injections and infusion should be considered • Ketorolac added to 0.5 percent Lidocaine for intravenous regional anesthesia (IVRA) provides effective anesthesia and analgesia
	Glucocorticoid steroid	<ul style="list-style-type: none"> • Dexamethasone 	<ul style="list-style-type: none"> • When added to nonopioid analgesics, time to discharge is reduced
	Lidocaine infusion	<ul style="list-style-type: none"> • Lidocaine 	<ul style="list-style-type: none"> • Treat neuropathic pain • Continued postop, may improve bowel function
	N-methyl-D-aspartate receptor antagonist	<ul style="list-style-type: none"> • Ketamine • Dextromethorphan 	<ul style="list-style-type: none"> • Higher doses of Ketamine may have psychotropic effects
	Nonsteroidal anti-inflammatory drug (NSAID)	<ul style="list-style-type: none"> • Ketorolac 	<ul style="list-style-type: none"> • Increased risk of gastrointestinal bleeding⁶⁹ • Concern for increased surgical site bleeding, limited evidence in the literature^{65,69}
	Opioid	<ul style="list-style-type: none"> • Opiates • Semi-synthetic opioids • Synthetic opioids • Mixed agonist-antagonist opioids 	<ul style="list-style-type: none"> • May cause nausea and vomiting, sedation⁷⁰ • Low to moderated dose(s) considered for anticipated moderate to severe pain
	Technology*	<ul style="list-style-type: none"> • Disposable local anesthetic infusion systems 	<ul style="list-style-type: none"> • Cost • Patient education • Plan for removal post-discharge
Postop	Acetanilide derivative	<ul style="list-style-type: none"> • Acetaminophen 	<ul style="list-style-type: none"> • IV or oral Acetaminophen
	Gabapentinoid	<ul style="list-style-type: none"> • Pregabalin • Gabapentin 	<ul style="list-style-type: none"> • Increased risk of sedation, confusion, ataxia, visual disturbances, and suicidal ideation⁶³ • Increased rate of postoperative adverse events in age > 65 years⁶³
	Ketamine infusion	<ul style="list-style-type: none"> • Ketamine 	<ul style="list-style-type: none"> • Controls refractory pain • Reverses opioid tolerance and hyperalgesia related to chronic opioid use
	Lidocaine infusion	<ul style="list-style-type: none"> • Lidocaine 	<ul style="list-style-type: none"> • Treat neuropathic pain • Continued postop, may improve bowel function

**This document is only for open comments and not final.
Do not cite or distribute.
Submit comments to practice@aana.com**

	Class of Medication/Technique*	Medication	Considerations
	Low to moderate dose IV or oral opioid for breakthrough pain	<ul style="list-style-type: none"> • Oxycodone • Morphine • Hydromorphone 	<ul style="list-style-type: none"> • Useful for acute treatment of moderate-to-severe pain • Increased risk of PONV, decrease in bowel motility⁷⁰
	Nonsteroidal anti-inflammatory drug (NSAID)	<ul style="list-style-type: none"> • Ibuprofen • Ketorolac 	<ul style="list-style-type: none"> • In some procedures may increase bleeding⁶⁹ • Increased risk of nausea and vomiting
	Oral dextromethorphan	<ul style="list-style-type: none"> • Dextromethorphan 	<ul style="list-style-type: none"> • Helpful for patients with chronic opioid use
	Technology*	<ul style="list-style-type: none"> • Transcutaneous electrical nerve stimulation (TENS) 	<ul style="list-style-type: none"> • Patient education to manage post-discharge

Draft

409 *Nausea/Vomiting Risk Assessment and Prophylaxis*

410 Proactive management of PONV is core to the patient returning to preprocedure health and
 411 activity⁴. Several risk factors for PONV include a history of PONV or motion sickness, being
 412 female, being a nonsmoker, having a surgical procedure, a surgical procedure lasting more than
 413 60 minutes, and the use of inhalation agents and/or opioids.⁴

414
 415 *PONV Risk Assessment*

416 Several validated tools for the assessment of PONV are available. The Apfel Score assesses the
 417 patient for four PONV risk factors: female gender, nonsmoking status, postoperative use of
 418 opioids, and previous history of PONV, or motion sickness.^{71,72} Each of the elements, if present,
 419 receives a score of 1 to predict the risk of PONV.

420 **Table 2.** Apfel Score to Predict Postoperative Nausea and Vomiting⁷¹⁻⁷⁴

					Score*
Female					
Nonsmoker					
Post-operative use of opioids					
Previous history of PONV or motion sickness					
Risk Factor(s) Present	0	1	2	3	4
Percent Risk of PONV	10	21	39	61	79

421 *Score 1 is present, 0 is absent

422

423 Strategies to reduce the risk of PONV include:^{71,74}

- 424 • Use regional anesthesia (rather than general anesthesia).
- 425 • Use of propofol for induction and maintenance of anesthesia.

- 426 • Avoid nitrous oxide.
- 427 • Avoid volatile anesthetics.
- 428 • Minimize opioids.
- 429 • Adequate hydration, while avoiding excessive fluid.

430

431 *Goal Directed Fluid Therapy*

432 Each element of the ERAS pathway is important to successful patient recovery. Euvolemia
433 through goal-directed fluid therapy (GDFT) is maintained in the intraoperative phase through
434 cardiac function monitoring to track the effects of small crystalloid or colloid boluses and
435 vasopressors on cardiac parameters instead of administering large volumes of clear intravenous
436 fluids without cardiac function monitoring. GDFT has been shown to reduce complications and
437 length of stay using non-invasive or invasive monitoring of varying cardiac function parameters,
438 depending on the monitoring platform, to maintain normovolemia, optimize cardiac function, and
439 decrease fluid and salt excess.^{75,76}

440

441 Evidence suggests that GDFT results in better patient outcomes compared to standard intra- and
442 post-operative fluid management. The age-old formula that calculated volume deficit from fasting,
443 insensible volume loss, hourly fluid rate, and crystalloid boluses to maintain blood pressure, heart
444 rate, and urine output is a reference from our past that has been shown to place the patient at risk
445 of complications and slow recovery.⁷⁷ A meta-analysis of 32 randomized controlled trials involving
446 5,056 patients showed a significant reduction in mortality in the high-risk (expected mortality > 20
447 percent) group.⁷⁸ Another study, which examined 29 randomized controlled trials involving 4,085
448 patients, also found a significant reduction in mortality and surgical complications for all patients.⁷⁹

449

450 To decrease variability in fluid administration during surgery and to improve outcomes, it is
451 important to tailor GDFT protocols to each patient's unique surgical and patient risk factors.⁸⁰ This
452 can be achieved with an individualized patient and procedure fluid management plan.^{81,82} GDFT
453 maintains intraoperative normovolemia by monitoring stroke volume, cardiac output, and/or oxygen
454 delivery to avoid hypovolemia and postoperative oxygen debt.^{81,83} Monitoring technologies include
455 esophageal doppler, arterial waveform analyzers, photoplethysmography-based devices, volume
456 clamp-based devices, and bioreactance devices.⁸⁴

457

458 *Active Warming*

459 Preoperative and intraoperative normothermia is another important element of the ERAS pathway
460 to decrease oxygen demand from shivering post-operatively, as well as to improve healing and
461 decrease the risk of surgical site infection.⁴ Core temperature should be regularly monitored and
462 maintained above 35.5-36°C in the intraoperative and immediate postoperative period.^{4,85}

463

464 *Glycemic Management*

465 Perioperative hyperglycemia is associated with an increased risk of morbidity and mortality.^{86,87}
466 Surgical patients may develop hyperglycemia as a result of the hypermetabolic stress response,
467 which is responsible for increased glucose production and insulin resistance.^{88,89} Overtreatment
468 and undertreatment of hyperglycemia present a significant risk to patients with and without
469 diabetes.⁹⁰ Factors that may affect optimal blood glucose control include concern for
470 overtreatment of hypoglycemia, clinical inertia to adopt policy, and medical management errors.⁹⁰
471
472 Early studies showed a significant reduction in postoperative complications when patients received
473 intensive insulin therapy to maintain glucose concentrations at 80-110 mg/dL or normoglycemia.
474 This management is also known as "tight" glucose control.⁹⁰ While current recommendations for

This document is only for open comments and not final.

Do not cite or distribute.

Submit comments to practice@aana.com

475 optimal perioperative blood glucose levels in critically ill patients vary (see Table 1), national
476 organizations agree that “tight” glucose control may not be beneficial. More recent studies found
477 no benefit and, in fact, identified an increased risk of complications related to “tight” glucose
478 control, including hypoglycemia.⁸⁶ In general, maintaining blood glucose concentrations of 180
479 mg/dL or less is recommended.^{91,92}

480

481 Other recommendations include minimizing changes to antidiabetic drugs if possible, performing a
482 hemoglobin A1C on all patients with diabetes or hyperglycemia if no A1C test result is available
483 from the previous 3 months, and considering postponing surgery if the patient is showing
484 complications of severe hyperglycemia (e.g., severe dehydration, diabetic ketoacidosis,
485 hyperosmotic hyperglycemia, nonketotic state).^{59,87,89}

486

487 **Table 3.** Recommendations for Optimal Preoperative Blood Glucose Range Levels

National Organization	Recommendations
American Diabetes Association (2024) ⁸⁷ and American Association of Clinical Endocrinology (2022) ⁹⁰	Target blood glucose level of 140 and 180 mg/dL
American College of Physicians (2011) ⁹³	Target blood glucose level of 140 to 200 mg/dL
Society of Ambulatory Anesthesia (2024) ⁵⁹	Target blood glucose level <180 mg/dL
Society of Thoracic Surgeons (2009) ⁹⁴	Target blood glucose level ≤180 mg/dL

488

489 *Tubes and Drains*

490 Whenever possible, the routine use of postoperative nasogastric or orogastric tubes, urinary
491 catheters, and abdominal and pelvic drains without clear indications should also be avoided.^{95,96}

492 These strategies help promote postoperative feeding and mobilization, avoid dehydration, and
493 promote patient comfort.⁹⁵

494

495 ***Postoperative Phase***

496 The facility delineates specific criteria for patient assessment, evaluation, monitoring, and
497 documentation intervals during the recovery period. The patient is assessed and evaluated, noting
498 the patient's recovery status and return to adequate function (e.g., level of consciousness, ability to
499 ambulate, etc.). For additional guidance, review AANA *Postanesthesia Care Standards for the*
500 *Certified Registered Nurse Anesthetist*.⁹⁷ Patients are encouraged to resume their normal diet and
501 activities of daily living on the day of surgery.⁹⁸ These activities are supported by capping or
502 removing the IV catheter, avoiding salt and water overload, preventing PONV, and administering
503 non-opioid and, when necessary, opioid analgesia.⁸¹

504

505

506 ***Discharge Phase***³⁰

507 Patients can be discharged after they meet the facility's criteria for recovery.³⁰ Refer to the Aldrete
508 score, or something similar, to determine the cognitive status of patients fit for discharge. These
509 criteria may include:

- 510 • Acceptable respiratory status.
- 511 • Hemodynamically stable within 20 percent of admission vital signs or as determined by the
512 facility.
- 513 • Ability to eat and drink without nausea or vomiting.
- 514 • Adequate pain control.
- 515 • Independently mobile; able to get out of bed and on/off the toilet or return to the level of
516 preprocedure activity.

- 517 • No complications requiring extended hospital care.

518

519 Prior to discharge, the patient continues to receive comprehensive education that began in their
520 surgeon's office related to anesthesia, surgical procedures, and pain management to address any
521 questions and concerns. The patient, family, or caregiver also receives written information that
522 includes instructions, symptoms to monitor for that need to be reported, who to report them to,
523 emergency contact information, and strategies to aid recovery (e.g., how to control pain with
524 medicine, how to care for the incisions).

525

526 ***Post-Discharge Phase***

527 The patient's ERAS pathway and the participation of the interprofessional team continue when
528 they return home. The patient is scheduled for follow-up appointments, as necessary, with the
529 surgeon, proceduralist, primary care, and/or specialty care clinician.³⁰ When indicated, additional
530 members of the team will be added to address specific patient needs.

531

532 **Continued Quality Improvement Team Activities**

533 Identification of desired ERAS pathway outcomes and facilities pre-ERAS pathway outcomes are
534 helpful to identify opportunities for improvement and education for pathway compliance and
535 outcomes. Several process and outcome measures, such as length of stay, readmission,
536 pneumonia, venous thromboembolism, urinary tract infection, and surgical site infection, are being
537 collected and reported by most facilities for several procedures. Considerations include:³⁰

- 538 • What data is currently being collected?
- 539 • What additional data should be collected?
- 540 • How will data be entered, analyzed, and reported?
- 541 • How to use the collected data?

542 ***What Data to Collect***

543 Developing a sustainable ERAS program requires tracking of outcomes and process measures.³⁴
544 While gathering data on every ERAS element may help improve patient outcomes, it may be
545 unrealistic to expect compliance with every ERAS element on every patient for a number of clinical
546 or process reasons.³⁴ It is important to consider a balanced approach to collecting information to
547 identify trends from available resources that can be used for process improvement. Data related to
548 an ERAS program may include:³⁰

- 549 • Demographics and physical characteristics (e.g., age, physical status, body mass index,
550 gender).
- 551 • Elements of patient health history (e.g., chronic pain, co-morbidities).
- 552 • Patient compliance with the elements (e.g., as a percentage or number of elements
553 chosen).
- 554 • Providers must comply with pathway elements within their specialty.
- 555 • Patient outcome measures:
 - 556 ○ Length of stay
 - 557 ○ Readmission
 - 558 ○ Surgical site infection
 - 559 ○ Surgical complication
 - 560 ○ Dehydration requiring IV fluids
 - 561 ○ Mortality rate
- 562 • Benefits and costs per patient in the pathway.

563 ***Data Collection***³⁰

- 564 • Use existing systems (if available) to collect baseline data:
 - 565 ○ Electronic health record(s) (EHR)

- 566 ○ The American College of Surgeons National Surgical Quality Improvement Program
- 567 (ACS NSQIP)
- 568 ○ Others
- 569 • Adapt or develop ERAS checklists for preoperative and perioperative care.
- 570 • Consider learning from existing facility data collection practices to improve the data
- 571 collection process.

572

573 ***Translating Data to Action***²⁴

574 Determine how best to analyze and communicate the ERAS pathway data to guide decision-

575 making for pathway improvement and individual practice compliance to match their peers. Data

576 may be posted and also shared at regular ERAS team meetings and through publications.

577

578 **Addressing Implementation Challenges**

579 Despite the well-established benefits of ERAS programs as effective and economically viable,

580 challenges arise when introducing ERAS pathways into routine practice.^{25,99} Barriers to

581 implementation may be attributed to patient-related, staff-related, and practice-related factors.

582

583 **Table 4.** Possible Barriers and Solutions to ERAS Pathway Development, Implementation, and

584 Compliance^{29,41,100}

	Barriers	Solutions
<ul style="list-style-type: none">• Patient-related	<ul style="list-style-type: none">• Needs and expectations• Health literacy, understanding and engagement• Attitudes and behaviors• Health history	<ul style="list-style-type: none">• Consistent communication and information• Agreed pathway• Ensure realistic expectations• Use of appropriate language

This document is only for open comments and not final.

Do not cite or distribute.

Submit comments to practice@aana.com

		and tools
<ul style="list-style-type: none"> • Staff-related 	<ul style="list-style-type: none"> • Attitudes and behaviors • Engagement • Communication and collaboration • Skills and competencies 	<ul style="list-style-type: none"> • Consistent communication and collaboration • Ongoing staff engagement, education and support
<ul style="list-style-type: none"> • Facility, Specialty-related 	<ul style="list-style-type: none"> • Leadership and support • Initial and ongoing staff education • Optimizing staff privileges and competencies • Availability of medications, monitoring and resources • Applicable policies and procedures • Use of data for continued pathway improvement 	<ul style="list-style-type: none"> • Regular reports documenting all aspects of ERAS process using data • Introducing an ERAS coordinator/specialist to focus on implementation and sustainability • Effective leadership • Data collection to observe what further improvements are needed and to highlight compliance and clinical outcomes

585 **Conclusion**

586 ERAS pathways contribute to positive patient outcomes,^{7,8} reduced postoperative
 587 complications,^{3,7,9} accelerated recovery,^{7,8} and early discharge,^{10,11} without increasing costs.^{9,12-15}
 588 Successful ERAS implementation depends on many factors, including effective patient and staff
 589 education, strong leadership within the interdisciplinary team, and strategic practice management.
 590 Anesthesia professionals are well positioned as champion leaders and members of the patient-
 591 centered team for ERAS excellence.

592

593 **Enhanced Recovery Resources**

This document is only for open comments and not final.

Do not cite or distribute.

Submit comments to practice@aana.com

- 594 • [American Society for Enhanced Recovery \(ASER\)](#)
- 595 • [ERAS Society Guidelines](#)
- 596 • [Peri-Operative Patient Simulation \(POPS\) – Intraoperative Goal Directed Fluid Therapy](#)
- 597 [Protocols](#)
- 598 • [University of California, San Francisco - Clinical Resources: ERAS Pathway](#)
- 599 • [AANA ERAS Resources](#)

600

601

602

603

Draft

**This document is only for open comments and not final.
Do not cite or distribute.
Submit comments to practice@aana.com**

604 **Table 5.** ERAS Pathway Development and Implementation Referencing Kotter, CUSP, and TeamSTEPS^{®23,24,30,33,41,101}

Phases	Kotter	CUSP	TeamSTEPS [®]	Implementation Considerations
Creating a climate for change	<ul style="list-style-type: none"> Establish a sense of urgency 	<ul style="list-style-type: none"> Understand the science of safety 	<ul style="list-style-type: none"> Create a change team 	<ul style="list-style-type: none"> Assess and analyze to identify themes of satisfaction, suggestions, and concerns in the current program Patient satisfaction and other feedback sources Benchmark U.S. and international sources for patient and community education communications and resources Assess the scope of the project Identify existing resources: <ul style="list-style-type: none"> Staff Equipment Drugs Clinical policies Education Documentation Identify facilitators and barriers Conduct an assessment of the readiness and capability Represent an inclusive, “can-do” attitude
	<ul style="list-style-type: none"> Create a guiding coalition 	<ul style="list-style-type: none"> Assemble the team Engage senior executive 	<ul style="list-style-type: none"> Define the problem 	<ul style="list-style-type: none"> Identify “champions” (e.g., nurses, anesthesia professionals, surgeons) to lead and facilitate the ERAS program Include patient advocate(s) on the leadership team
	<ul style="list-style-type: none"> Communicate the vision for change 	<ul style="list-style-type: none"> Understand the science of safety Identify defects through sensemaking 	<ul style="list-style-type: none"> Define the intervention 	<ul style="list-style-type: none"> Clearly communicate and engage others in the vision Obtain “buy-in” from all the members of the practice Partner with community leaders to develop messaging through multiple channels to communicate understanding of patient and family responsibility, and engage service agencies in pre- and post-care support services to increase safety, satisfaction, and outcomes
Introducing New Practice	<ul style="list-style-type: none"> Empower broad-based action, remove obstacles 	<ul style="list-style-type: none"> Assemble the team Identify defects through sensemaking Implement teamwork and communication 	<ul style="list-style-type: none"> Developing a plan for testing the effectiveness 	<ul style="list-style-type: none"> Develop and pilot the ERAS pathway in one surgical specialty Begin with a small team Develop initial learning, ongoing education, training, and continued team development Conduct a systematic review of the literature and facility outcome data Utilize patient feedback in developing the care pathways

**This document is only for open comments and not final.
Do not cite or distribute.
Submit comments to practice@aana.com**

Phases	Kotter	CUSP	TeamSTEPPS [®]	Implementation Considerations
		n		
Maintaining the Momentum	<ul style="list-style-type: none"> • Generate short-term wins 	<ul style="list-style-type: none"> • Implement teamwork and communication 	<ul style="list-style-type: none"> • Develop an implementation plan 	<ul style="list-style-type: none"> • Utilize electronic health records (EHRs) to track progress • Celebrate initial and new successes • Recognize staff and patient excellence
	<ul style="list-style-type: none"> • Consolidate and build on change 	<ul style="list-style-type: none"> • Identify defects through sensemaking 	<ul style="list-style-type: none"> • Develop a plan for sustained improvement 	<ul style="list-style-type: none"> • Develop outcome and process measures to track quality for continued improvement • Use outcome and process measures to track quality. Use data or audit feedback to make modifications • Audit all steps for compliance, review, and process • Audit documentation and patient compliance with care • Seek both positive feedback and opportunities to improve from patients and family • When possible, acquire patient and family assessments of care in real time to address less than satisfactory experiences
	<ul style="list-style-type: none"> • Anchor ERAS pathway changes into the organization and team culture 	<ul style="list-style-type: none"> • Understanding the science of safety • Implement teamwork and communication 	<ul style="list-style-type: none"> • Develop a communication plan 	<ul style="list-style-type: none"> • View the ERAS program as a continuum and not as a final destination • Leadership presence, participation, and ongoing support • Initial and ongoing staff education and training • Frequent updates on the successes, challenges, and solutions being addressed by ERAS • Continue educating the patient and community on the significance and importance of ERAS • Celebration of short-term wins

605
606
607
608
609

**This document is only for open comments and not final.
Do not cite or distribute.
Submit comments to practice@aana.com**

ERAS Phase	Goal	Considerations
Preoperative Phase	<ul style="list-style-type: none"> Engage the patient as a contributor and participant in their plan of care 	<ul style="list-style-type: none"> Provide detailed instructions prior to the procedure or surgery Provide necessary resources and services for the Preoperative Phase A light meal up to 6 hours preoperatively Carbohydrate beverage up to 2 hours preoperatively Initial multimodal medications and/or regional block placement Seek the patient's expectations Encourage the patient to ask questions and be an active participant in care decisions
	<ul style="list-style-type: none"> Discharge planning begins before admission 	<ul style="list-style-type: none"> Discuss discharge planning, education, and a home medication plan with the patient and family/friends in the surgeon's office, and during preanesthesia assessment optimization and care planning Encourage patients to ask questions and be active participants in care decisions Provide the patient with written pamphlets, handouts, and/or web resources
Intraoperative phase		<ul style="list-style-type: none"> Opioid sparing, multimodal analgesia Normovolemia/goal-directed fluid therapy Nausea/vomiting prophylaxis Normothermia Normoglycemia Avoid tubes and drains
Postoperative Phase	<ul style="list-style-type: none"> Encourage the patient to resume normal activities 	<ul style="list-style-type: none"> Multimodal analgesia Nausea/vomiting treatment No or judicious IV fluid management Ambulation on the day of surgery Normal diet on the day of surgery
	<ul style="list-style-type: none"> Discharge 	<ul style="list-style-type: none"> Anticipate needs for discharge Provide patient or family education Defined discharge criteria and patient/family education Engage with the interprofessional team and family to understand how to return to health and symptoms to be aware of in order to seek appropriate help
Post-Discharge Phase	<ul style="list-style-type: none"> Continue to support the patient to monitor for symptoms or changes in health and seek assistance Patient follow up with surgeon, proceduralist, primary care, and/or specialty care Continue therapy and other interprofessional activities as planned 	
Continued Quality Improvement Team Activities	<ul style="list-style-type: none"> Determine how best to analyze and communicate the ERAS pathway data to guide decision-making for pathway improvement and individual practice compliance Analyze and share quality measures, patient surveys, and staff input to celebrate successes and identify opportunities for improvement Utilize patient feedback to improve the ERAS program 	

610

611 Adopted by AANA Board of Directors July 2017
612 Revised by AANA Board of Directors TBD

613
614 © Copyright 2017

615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643

Appendix A. Sample Enhanced Recovery after Surgery Pathway Continuum to Develop Pathway and Team Engagement

MPerioperative Phase	Responsibility					
	Surgeon	Nurse	Anesthesia	Patient	Physical Therapist	Others as Needed
Prehospital/Preadmission Phase						
• For patient/family education						
• Pain management plan	Include patient's advanced pain management team as needed					
• Patient optimization	Include primary and specialty medicine as needed					
• Prehabilitation of select patients (e.g., diabetic, hypertensive)						
Preoperative Phase						
• Limited fasting (light meal up to 6 hours preop)						
• Carbohydrate beverage (up to 2 hours preop)						
• Initial multimodal medications and/or regional block placement						

This document is only for open comments and not final.

Do not cite or distribute.

Submit comments to practice@aana.com

• Discharge planning, education and home medication plan						
Intraoperative Phase						
• Opioid-free or opioid sparing multimodal analgesia						
• Normovolemia						
• Nausea/vomiting prophylaxis						
• Normothermia						
• Normoglycemia						
• Avoid tubes and drains						
Postoperative Phase						
• Early nutrition						
• Early mobilization					As needed	
• Multimodal analgesia emphasizing non-opioid techniques						
• Nausea/vomiting management						
• No or judicious IV fluid management						
• Patient/family education						
Post-Discharge Phase						
• Monitor for symptoms or changes in health to seek assistance						
• Follow-up with surgeon, proceduralist, primary care and/or specialty care						
• Continue therapy and other activities for recovery as planned						
Continued Quality Improvement Team Activities						
• Use data to celebrate successes and identify opportunities for improvement						

646